FDA approves Nevisense 3.0 for melanoma detection

The FDA has approved Nevisense 3.0, an artificial intelligence system for early melanoma detection, SciBase announced in a press release.

The third generation of the Nevisense platform is a more streamlined, efficient version of the system that was previously approved by the FDA, the release said.

“The release of Nevisense 3.0 in late 2018 in Germany and the EU has been the catalyst for five consecutive quarters of growth, and we see this as step one of our strategic plan” Simon Grant, CEO of SciBase, said in the release. “Receiving U.S. approval means that we can focus on step two of our strategy, which is to increase our marketing and sales activities in the U.S. based on our deep market experience with Nevisense 3.0 in Germany and the positioning we have developed for Nevisense in the U.S.”